자가면역질환 치료제 시장 : 치료법별, 질환별, 투여 경로별, 치료 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Autoimmune Disease Therapeutics Market is projected to grow by USD 382.33 billion at a CAGR of 10.52% by 2032.

Autoimmune disease therapeutics address a broad set of chronic, immune-mediated conditions, including rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. The National Institutes of Health recognizes more than 80 autoimmune diseases, many of which require long-term disease control rather than episodic treatment.

The market is being shaped by the expansion of biologics, biosimilars, targeted synthetic disease-modifying therapies, and precision immunology approaches. Demand is supported by earlier diagnosis, improved specialist referral pathways, and a growing emphasis on treat-to-target care models that measure remission, relapse prevention, organ protection, steroid-sparing benefits, and patient-reported outcomes.

Transformative Shifts in the Autoimmune Therapeutics Landscape

The autoimmune therapeutics landscape is shifting from broad immunosuppression toward pathway-specific immune modulation. Monoclonal antibodies, fusion proteins, Janus kinase inhibitors, TYK2 inhibition, B-cell depletion, interleukin blockade, integrin targeting, sphingosine-1-phosphate receptor modulation, and complement-directed strategies are enabling more individualized treatment decisions across inflammatory, dermatologic, neurologic, gastrointestinal, and rheumatologic indications.

At the same time, biosimilar adoption is changing payer negotiations and treatment access. Regulatory agencies, including the FDA and EMA, continue to support biosimilar pathways, while safety communications around some immunomodulators, including JAK inhibitors, have increased the importance of risk stratification, post-marketing surveillance, infection screening, vaccination planning, and shared decision-making between clinicians and patients.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across autoimmune drug discovery, clinical development, and commercialization. AI-supported target identification, multi-omics analysis, imaging interpretation, digital biomarkers, natural language processing, and real-world evidence analytics are helping researchers understand disease heterogeneity and identify patient subgroups more likely to respond to specific mechanisms of action.

In clinical operations, AI can improve protocol design, site selection, eligibility screening, adverse event detection, and patient retention when deployed with appropriate governance. For industry leaders, the strongest near-term value is expected where AI augments regulated workflows, supports pharmacovigilance, improves literature monitoring, and accelerates evidence generation without replacing clinical judgment or validated regulatory standards.

Key Regional Insights

North America remains a leading region for autoimmune disease therapeutics due to high specialist density, mature reimbursement systems, large clinical trial networks, and rapid uptake of innovative biologics and targeted therapies. The United States anchors regional activity through FDA approvals, payer-driven formulary management, specialty pharmacy infrastructure, and extensive real-world evidence generation, while Canada contributes through public-private care pathways, health technology assessment, and provincial reimbursement decision-making.

Europe benefits from centralized EMA regulatory processes, strong national reimbursement systems, established treatment guidelines, and broad biosimilar utilization, particularly across European Union markets. Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, Australia, and ASEAN health systems expand clinical development, biologics manufacturing, specialty care access, and patient assistance programs. Latin America shows rising demand through Brazil and Mexico as biosimilar availability, public procurement, and private insurance coverage shape access. The Middle East is advancing through hospital modernization and specialty medicine procurement in GCC health systems, while Africa remains highly heterogeneous, with autoimmune therapy adoption influenced by affordability, diagnostic capacity, specialist availability, cold-chain infrastructure, and reimbursement maturity.

Key Group Insights

The European Union is a major policy and access environment for autoimmune disease therapeutics, with centralized regulatory review, national pricing negotiations, health technology assessment processes, and strong biosimilar experience shaping competitive dynamics. G7 countries collectively influence clinical standards, payer evidence requirements, pharmacovigilance expectations, launch sequencing, and adoption of advanced immunology products through mature regulatory systems and specialist care networks.

BRICS markets are increasingly important for local manufacturing, clinical trial diversification, and broader treatment access, particularly as China, India, and Brazil expand biopharmaceutical capabilities and Russia prioritizes domestic registration and supply resilience. ASEAN markets offer long-term growth as health systems invest in specialty care, biologics access, and referral infrastructure, while GCC countries are prioritizing advanced hospital capacity, digital health systems, and access to innovative medicines. NATO membership is not a healthcare market grouping, but many NATO countries overlap with high-income European and North American systems that maintain advanced regulatory, procurement, pharmacovigilance, and clinical research capacity.

Key Country Insights

The United States leads autoimmune therapeutics innovation through extensive biomedical R&D activity, strong FDA regulatory infrastructure, broad clinical trial participation, and rapid specialty drug launches, while Canada emphasizes evidence-based reimbursement, health technology assessment, and equitable access across provincial systems. Mexico and Brazil are important Latin American markets where public procurement, private insurance, domestic regulatory pathways, and biosimilar availability affect therapy adoption.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to clinical research, guideline-led care, health technology assessment, and biosimilar-driven cost management, while Russia remains influenced by local registration, procurement policy, and manufacturing priorities. China is expanding biologics development, domestic innovation, and autoimmune clinical trial activity; India is strengthening biosimilar and cost-effective manufacturing capacity; Japan maintains high regulatory standards, specialist care access, and aging-population-driven demand for chronic disease management; South Korea is globally competitive in biosimilars and biologics manufacturing; and Australia supports advanced autoimmune care through structured reimbursement, specialist networks, and clinical guidelines.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, biomarker-supported patient selection, and evidence packages that demonstrate durable remission, relapse reduction, organ protection, steroid-sparing benefits, safety, and quality-of-life improvements. Commercial strategies should prepare for biosimilar competition, payer step therapy, indication-specific value assessments, and evolving treatment sequencing across rheumatology, dermatology, gastroenterology, neurology, endocrinology, and nephrology.

Organizations should also invest in real-world evidence, pharmacovigilance automation, patient support programs, adherence tools, and equitable access models. Partnerships with academic centers, specialty networks, diagnostics developers, contract research organizations, and AI-enabled analytics providers can improve trial precision, accelerate market access dossiers, and support lifecycle expansion across related autoimmune indications.

Research Methodology

This executive summary is based on secondary research from publicly available and authoritative sources, including regulatory agency materials, clinical trial registries, peer-reviewed literature, health technology assessment frameworks, treatment guidelines, pharmacovigilance updates, and recognized public health references such as NIH, FDA, EMA, WHO, and OECD resources where applicable.

The methodology emphasizes triangulation across clinical, regulatory, commercial, and regional indicators. Insights were validated by comparing disease burden evidence, treatment guidelines, product class developments, biosimilar policy trends, safety communications, reimbursement dynamics, and regional access conditions to identify consistent patterns shaping the autoimmune disease therapeutics market.

Conclusion

Autoimmune disease therapeutics are entering a more precise, evidence-intensive phase defined by biologic innovation, targeted oral therapies, biosimilar competition, improved safety monitoring, and AI-enabled development models. The strongest opportunities will emerge for organizations that can combine clinical differentiation with safety transparency, payer-relevant outcomes, and scalable access strategies.

As regional markets mature at different speeds, success will depend on aligning scientific innovation with local reimbursement realities, specialist capacity, regulatory expectations, and patient needs. Organizations that integrate precision medicine, real-world evidence, responsible AI, and equitable access planning into development and commercialization will be best positioned to lead the next phase of autoimmune care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autoimmune Disease Therapeutics Market, by Therapeutic Types

• 7.1. Antihyperglycemics
• 7.2. Biologics
  • 7.2.1. Fusion Proteins
  • 7.2.2. Gene Therapy
  • 7.2.3. Monoclonal Antibodies
• 7.3. Cytokine Inhibitors
• 7.4. Immunomodulators
• 7.5. Immunosuppressants
• 7.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 7.7. Phosphodiesterase Inhibitors
• 7.8. Small Molecules
  • 7.8.1. Corticosteroids
  • 7.8.2. JAK Inhibitors

8. Autoimmune Disease Therapeutics Market, by Disease Type

• 8.1. Inflammatory Bowel Disease
• 8.2. Lupus Erythematosus
• 8.3. Multiple Sclerosis
• 8.4. Psoriasis
• 8.5. Rheumatoid Arthritis
• 8.6. Type 1 Diabetes

9. Autoimmune Disease Therapeutics Market, by Route of Administration

• 9.1. Injectable
  • 9.1.1. Intramuscular
  • 9.1.2. Intravenous
  • 9.1.3. Subcutaneous
• 9.2. Oral

10. Autoimmune Disease Therapeutics Market, by Therapeutic Application

• 10.1. Disease Progression Alteration
• 10.2. Immune System Modulation
• 10.3. Pain Management
• 10.4. Reduction of Inflammation

11. Autoimmune Disease Therapeutics Market, by End-User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Research Institutes

12. Autoimmune Disease Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Autoimmune Disease Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Autoimmune Disease Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amgen Inc.
• 16.4. AstraZeneca PLC
• 16.5. Beckman Coulter, Inc.
• 16.6. Bio-Rad Laboratories, Inc.
• 16.7. BioAgilytix Labs, LLC
• 16.8. bioMerieux S.A.
• 16.9. Bristol-Myers Squibb Company
• 16.10. Eli Lilly and Company
• 16.11. Exagen, Inc.
• 16.12. F. Hoffmann-La Roche Ltd.
• 16.13. GlaxoSmithKline PLC
• 16.14. Johnson & Johnson Services, Inc.
• 16.15. Lupin Limited
• 16.16. Merck & Co., Inc.
• 16.17. Novartis AG
• 16.18. Pfizer, Inc.
• 16.19. Sanofi S.A.
• 16.20. Siemens Healthineers AG
• 16.21. Thermo Fisher Scientific Inc.
• 16.22. Trinity Biotech PLC
• 16.23. UCB S.A.
• 16.24. Werfen S.A.